Skip to main content
Premium Trial:

Request an Annual Quote

BioIVT Xpressway Profile Safety Package

BioIVT has launched the Xpressway Profile Safety Package, a compendium of 46 expression profiles for genes known to play pivotal roles in drug safety assessments. These genes are included in the initial screening panel used by pharmaceutical companies to evaluate new chemical entities for potential off-target interactions and toxic effects. Once these entities have been screened against the 46 target genes, the Xpressway Profile Safety Package allows the resulting binding data to be compared with the corresponding human target expression profiles and interpreted further to assess potential safety risk, the company said. When NCEs bind to the targets, the tissue distribution of those targets can inform decision making about the compounds and chemical series. BioIVT said that it employed a rigorous, highly controlled qRT-PCR method to develop the Xpressway Profile Safety Package's gene expression data.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.